NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Forecast, Price & News $13.57 -0.14 (-1.02%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$13.19▼$13.8250-Day Range$12.90▼$17.4552-Week Range$12.29▼$30.79Volume34,667 shsAverage Volume68,723 shsMarket Capitalization$375.21 millionP/E RatioN/ADividend YieldN/APrice Target$37.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aerovate Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside172.7% Upside$37.00 Price TargetShort InterestBearish8.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingSelling Shares$750,605 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.82) to ($2.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector789th out of 970 stocksPharmaceutical Preparations Industry374th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingAerovate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.00, Aerovate Therapeutics has a forecasted upside of 172.7% from its current price of $13.57.Amount of Analyst CoverageAerovate Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.29% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.Change versus previous monthShort interest in Aerovate Therapeutics has recently increased by 5.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAerovate Therapeutics does not currently pay a dividend.Dividend GrowthAerovate Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTE. Previous Next 3.0 News and Social Media Coverage News SentimentAerovate Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aerovate Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for AVTE on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Aerovate Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerovate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $750,605.00 in company stock.Percentage Held by Insiders19.30% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aerovate Therapeutics are expected to grow in the coming year, from ($2.82) to ($2.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerovate Therapeutics is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerovate Therapeutics is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerovate Therapeutics has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aerovate Therapeutics (NASDAQ:AVTE) StockAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More AVTE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTE Stock News HeadlinesAugust 14, 2023 | finance.yahoo.comAerovate Therapeutics Announces Second Quarter Financial Results and Business HighlightsAugust 14, 2023 | finance.yahoo.comAerovate Therapeutics Announces Second Quarter Financial Results and Business HighlightsSeptember 30, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.July 11, 2023 | finance.yahoo.comAerovate Therapeutics Appoints Habib Dable To Its Board of DirectorsJune 28, 2023 | seekingalpha.comAerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAHJune 23, 2023 | finance.yahoo.comTENX: Notice of Allowance Increases ConfidenceJune 22, 2023 | marketwatch.com8-K: Aerovate Therapeutics, Inc.May 23, 2023 | msn.comPeter Kolchinsky-led RA Capital’s New Positions Feature CureVac, Mineralys, Pilant, Enliven TherapeuticsSeptember 30, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 22, 2023 | finance.yahoo.comAerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International ConferenceMay 17, 2023 | markets.businessinsider.comAerovate Therapeutics (AVTE) Receives a Buy from WedbushMay 16, 2023 | msn.comAerovate Therapeutics GAAP EPS of -$0.67 misses by $0.07May 16, 2023 | finanznachrichten.deAerovate Therapeutics, Inc.: Aerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsMay 15, 2023 | msn.comRecap: Aerovate Therapeutics Q1 EarningsMay 15, 2023 | finance.yahoo.comAerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsMay 15, 2023 | finance.yahoo.comAerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsApril 12, 2023 | seekingalpha.comAerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH MarketMarch 30, 2023 | finanznachrichten.deAerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business HighlightsMarch 29, 2023 | finance.yahoo.comAerovate Therapeutics Announces Full-Year 2022 Financial Results and Business HighlightsMarch 9, 2023 | benzinga.comAerovate Therapeutics Chief Executive Officer Awarded $3.29M Worth of Stock OptionsMarch 3, 2023 | msn.comGuggenheim Initiates Coverage of Aerovate Therapeutics (AVTE) with Buy RecommendationMarch 2, 2023 | finance.yahoo.comAerovate Therapeutics to Present at Cowen 43rd Annual Health Care ConferenceJanuary 23, 2023 | finance.yahoo.comAerovate Therapeutics Appoints Donald Santel To Its Board of DirectorsDecember 31, 2022 | finance.yahoo.comCalculating The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)December 28, 2022 | finance.yahoo.com12 Best Performing Biotech Stocks in 2022December 6, 2022 | finance.yahoo.comAnalyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program ThesisNovember 17, 2022 | finance.yahoo.comAerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open ResearchSee More Headlines Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTE Company Calendar Last Earnings8/14/2023Today9/30/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVTE CUSIPN/A CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees43Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.00 High Stock Price Forecast$48.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+172.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.26% Return on Assets-45.57% Debt Debt-to-Equity RatioN/A Current Ratio11.48 Quick Ratio11.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.19 per share Price / Book2.61Miscellaneous Outstanding Shares27,650,000Free Float22,314,000Market Cap$375.21 million OptionableNot Optionable Beta0.37 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Timothy P. Noyes M.B.A. (Age 61)CEO & Director Comp: $703.8kMr. George A. Eldridge (Age 60)CFO & Treasurer Comp: $533.89kDr. Marinus Verwijs Ph.D. (Age 47)Chief Technical Officer Comp: $439.88kDr. Benjamin T. Dake Ph.D. (Age 47)Founder, Pres, COO & Sec. Dr. Ralph W. Niven M.B.A. (Age 63)M.R, Ph.D., Pharm.S, Chief Scientific Officer Mr. Hunter Gillies M.D. (Age 57)Chief Medical Officer Mr. Timothy J. Pigot (Age 52)Chief Commercial Officer Ms. Donna DeaHead of Regulatory AffairsMs. Susan FischerSr. VP of Devel. OperationsMr. Stephen K. YuSr. VP of QualityMore ExecutivesKey CompetitorsUroGen PharmaNASDAQ:URGNAldeyra TherapeuticsNASDAQ:ALDXArcutis BiotherapeuticsNASDAQ:ARQTARS PharmaceuticalsNASDAQ:SPRYPrecigenNASDAQ:PGENView All CompetitorsInsiders & InstitutionsBarclays PLCSold 1,314 shares on 9/21/2023Ownership: 0.012%Benjamin T DakeSold 3,931 sharesTotal: $59,200.86 ($15.06/share)California State Teachers Retirement SystemSold 1,063 shares on 8/21/2023Ownership: 0.036%HighVista Strategies LLCBought 25,970 shares on 8/15/2023Ownership: 0.151%Alliancebernstein L.P.Bought 11,720 shares on 8/15/2023Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions AVTE Stock - Frequently Asked Questions Should I buy or sell Aerovate Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVTE shares. View AVTE analyst ratings or view top-rated stocks. What is Aerovate Therapeutics' stock price forecast for 2023? 3 equities research analysts have issued 12 month target prices for Aerovate Therapeutics' shares. Their AVTE share price forecasts range from $27.00 to $48.00. On average, they predict the company's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 172.7% from the stock's current price. View analysts price targets for AVTE or view top-rated stocks among Wall Street analysts. How have AVTE shares performed in 2023? Aerovate Therapeutics' stock was trading at $29.30 at the beginning of 2023. Since then, AVTE shares have decreased by 53.7% and is now trading at $13.57. View the best growth stocks for 2023 here. Are investors shorting Aerovate Therapeutics? Aerovate Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,430,000 shares, an increase of 5.9% from the August 31st total of 1,350,000 shares. Based on an average trading volume of 71,500 shares, the days-to-cover ratio is currently 20.0 days. Approximately 8.3% of the company's shares are sold short. View Aerovate Therapeutics' Short Interest. When is Aerovate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our AVTE earnings forecast. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.07. When did Aerovate Therapeutics IPO? (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share. What is Aerovate Therapeutics' stock symbol? Aerovate Therapeutics trades on the NASDAQ under the ticker symbol "AVTE." How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aerovate Therapeutics' stock price today? One share of AVTE stock can currently be purchased for approximately $13.57. How much money does Aerovate Therapeutics make? Aerovate Therapeutics (NASDAQ:AVTE) has a market capitalization of $375.21 million. The company earns $-51,510,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. How can I contact Aerovate Therapeutics? The official website for the company is aerovatetx.com. The company can be reached via phone at 617-443-2400 or via email at ir@aerovatetx.com. This page (NASDAQ:AVTE) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.